title: Natalizumab discontinuation: an increasingly tricky proposition.
authors: T W
authors: TW
authors: West
authors: J
authors: J
authors: Killestein
authors: R J
authors: RJ
authors: Fox
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D011358:Product Surveillance, Postmarketing
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab